- Home
- ITCI vs RPRX Comparison
ITCI vs RPRX Comparison
Compare ITCI & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITCI
- RPRX
- Stock Information
- Founded
- ITCI 2002
- RPRX 1996
- Country
- ITCI United States
- RPRX United States
- Employees
- ITCI N/A
- RPRX N/A
- Industry
- ITCI Biotechnology: Pharmaceutical Preparations
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- ITCI Health Care
- RPRX Health Care
- Exchange
- ITCI Nasdaq
- RPRX Nasdaq
- Market Cap
- ITCI 13.5B
- RPRX 13.9B
- IPO Year
- ITCI N/A
- RPRX 2020
- Fundamental
- Price
- ITCI $126.97
- RPRX $31.29
- Analyst Decision
- ITCI Buy
- RPRX Strong Buy
- Analyst Count
- ITCI 13
- RPRX 6
- Target Price
- ITCI $103.62
- RPRX $41.67
- AVG Volume (30 Days)
- ITCI 5.8M
- RPRX 4.4M
- Earning Date
- ITCI 02-20-2025
- RPRX 02-11-2025
- Dividend Yield
- ITCI N/A
- RPRX 2.81%
- EPS Growth
- ITCI N/A
- RPRX 518.56
- EPS
- ITCI N/A
- RPRX 2.55
- Revenue
- ITCI $613,728,000.00
- RPRX $2,266,003,000.00
- Revenue This Year
- ITCI $48.43
- RPRX $14.54
- Revenue Next Year
- ITCI $38.10
- RPRX $10.94
- P/E Ratio
- ITCI N/A
- RPRX $12.24
- Revenue Growth
- ITCI 46.08
- RPRX N/A
- 52 Week Low
- ITCI $62.78
- RPRX $24.05
- 52 Week High
- ITCI $128.00
- RPRX $32.21
- Technical
- Relative Strength Index (RSI)
- ITCI 84.04
- RPRX 69.95
- Support Level
- ITCI $126.88
- RPRX $29.73
- Resistance Level
- ITCI $127.36
- RPRX $32.21
- Average True Range (ATR)
- ITCI 0.44
- RPRX 0.61
- MACD
- ITCI -0.90
- RPRX -0.03
- Stochastic Oscillator
- ITCI 55.86
- RPRX 61.77
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.